Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial

FRANKFURT (Reuters) - Germany's Merck KGaA said on Tuesday that its cancer immunotherapy avelumab, jointly developed with Pfizer, failed to improve overall survival compared with standard chemotherapy in a late-stage study on gastric cancer patients.

from Reuters: Health News http://ift.tt/2nbSIhE